Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Pharmacol Res. 2022 Sep 28;185:106476. doi: 10.1016/j.phrs.2022.106476

Figure 5. Differential effects of PG01042, PG01037, and VK4-116 on L-DOPA-induced dyskinesia.

Figure 5.

In a within-subjects, counterbalanced design, hemiparkinsonian rats previously rendered dyskinetic were treated with the D3R ligands (a) PG01042 (0, 5, 10 mg/kg; i.p.), (b) PG01037 (0, 10, 30 mg/kg; i.p.), or (c) VK4-116 (VK; 0, 10, 30 mg/kg; i.p.) prior to administration of L-DOPA (6 mg/kg; s.c.). Rats were rated for Axial, Limb and Orolingual (ALO) abnormal involuntary movements (AIMs) every 10 min for 180 min post-injection. AIMs time course and ALO sums are expressed as median + median absolute deviation (M.A.D.). Data were analyzed by non-parametric Friedman ANOVAs with Wilcoxon Match Pairs post-hoc tests. + p < 0.05 for Vehicle versus low dose, # p < 0.05 for vehicle versus high dose, $ p < 0.05 for low dose versus high dose.